Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach(Front. Oncol., (2022), 11, (783803), 10.3389/fonc.2021.783803)

Tai, Yee KitYee KitTaiChan, Karen Ka WingKaren Ka WingChanFong, Charlene Hui HuaCharlene Hui HuaFongRamanan, SharanyaSharanyaRamananYap, Jasmine Lye YeeJasmine Lye YeeYapYin, Jocelyn NaixinJocelyn NaixinYinYip, Yun ShengYun ShengYipTan, Wei RenWei RenTanKoh, Angele Pei FernAngele Pei FernKohTan, Nguan SoonNguan SoonTanChan, Ching WanChing WanChanRUBY YUN-JU HUANGLi, Jing ZeJing ZeLiFröhlich, JürgJürgFröhlichFranco-Obregón, AlfredoAlfredoFranco-Obregón2023-01-162023-01-162022-04-202234-943Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/627258In the original article, there was a nonconsequential error in Figure 1 as published. A fileconcatenation error occurred within the FACS analysis software that implicated the scatter dotplots shown in Figure 1C. The corrected Figure 1 appears below.enbreast cancerchemotherapychorioallantoic membranedoxorubicinEMTpatient-derived xenograftPEMFsTRPC1Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach(Front. Oncol., (2022), 11, (783803), 10.3389/fonc.2021.783803)corrigendum10.3389/fonc.2022.892408355151352-s2.0-85129541364WOS:000876246900001https://api.elsevier.com/content/abstract/scopus_id/85129541364